Evidence map›Paper›PMID 15452555›Full record

ArticleProstate cancer and prostatic diseases2004

5alpha-Androstane-3alpha,17beta-diol activates pathway that resembles the epidermal growth factor responsive pathways in stimulating human prostate cancer LNCaP cell proliferation.

R A Zimmerman, I Dozmorov, E H Nunlist, Y Tang, X Li, R Cowan, M Centola, M B Frank, D J Culkin, H-K Lin

Abstract read
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

R A ZimmermanDepartment of Urology, University of Oklahoma Health Sciences Center, 920 Stanton L Young Blvd, Oklahoma City, OK 73104, USA.
I Dozmorov
E H Nunlist
Y Tang
X Li
R Cowan
M Centola
M B Frank
D J Culkin
H-K Lin
Oklahoma Medical Research Foundation · USUniversity of Oklahoma · USUniversity of Oklahoma Health Sciences Center · US

Funding

HUMAN PROSTATIC 3A HYDROXYSTEROID DEHYDROGENASER01DK054925 · NIDDK · WASHINGTON UNIVERSITY · PI LIN, HSUEH-KUNG · 1998 to 2002
$447k
NIDDK NIH HHS DK54925
6 · The paper itself

Abstract

5alpha-Androstane-3alpha,17beta-diol (3alpha-diol) is considered to have no androgenic effects in androgen target organs unless it is oxidized to 5alpha-dihydrotestosterone (5alpha-DHT). We used microarray and bioinformatics to identify and compare 3alpha-diol and 5alpha-DHT responsive gene in human prostate LNCaP cells. Through a procedure called 'hypervariable determination', a similar set of 30 responsive genes involving signal transduction, transcription regulation, and cell proliferation were selected in 5alpha-DHT-, 3alpha-diol-, and epidermal growth factor (EGF)-treated samples. F-means cluster and networking procedures showed that the responsive pattern of these genes was more closely related between 3alpha-diol and EGF than between 5alpha-DHT and 3alpha-diol treatments. We conclude that 3alpha-diol is capable of stimulating prostate cell proliferation by eliciting EGF-like pathway in conjunction with androgen receptor pathway.

Indexed as

Signal TransductionAnabolic AgentsAndrostane-3,17-diolCell ProliferationComputational BiologyEpidermal Growth FactorGene Expression ProfilingHumansMaleOligonucleotide Array Sequence AnalysisProstatic NeoplasmsReceptors, AndrogenTumor Cells, CulturedAnabolic AgentsAndrostane-3,17-diolEpidermal Growth FactorReceptors, Androgen

Identifiers

PMID15452555
OpenAlexW2040581408

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.